Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Micardis® (Drug); MicardisPlus® (Drug)
Phase: N/A
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
The primary objective was to evaluate the effect of the treatment with Micardis® or
MicardisPlus® on blood pressure. Secondary objectives were the effect of Micardis® /
MicardisPlus® on metabolic parameters (triglycerides, cholesterol, LDL blood glucose,
insulin Homeostasis Model Assessment (HOMA)-index and HbA1c) in patients with essential
hypertension and diabetes mellitus
Clinical Details
Official title: Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Change from Baseline in systolic blood pressure (SBP)Change from Baseline in diastolic blood pressure (DBP)
Secondary outcome: Assessment of efficacy by investigator on a 6-point scaleAssessment of metabolic effect on a 3-point scale Change from Baseline in laboratory parameters Assessment of tolerability by investigator on a 5-point scale Number of patients with adverse events
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age > 18 years
- Hypertension
- Diabetes mellitus
Exclusion Criteria:
- Age < 18 years
Locations and Contacts
Additional Information
Starting date: January 2006
Last updated: September 16, 2014
|